Upsher-Smith Laboratories

UPSHER-SMITH LAUNCHES METHIMAZOLE TABLETS, USP

Retrieved on: 
Friday, March 29, 2024
AB, USP, RLD, Upsher-Smith Laboratories

MAPLE GROVE, Minn., March 29, 2024 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of Methimazole Tablets, USP, 5 mg and 10 mg.

Key Points: 
  • MAPLE GROVE, Minn., March 29, 2024 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of Methimazole Tablets, USP, 5 mg and 10 mg.
  • The Methimazole Tablet market had U.S. sales of approximately $36.8 million for the 12 months ending December 2023 according to IQVIA.
  • The Therapeutic Equivalence (TE) code for the product is AB, and the original Reference Listed Drug (RLD) was the brand Tapazole®*.

Tonix Pharmaceuticals to Participate in the 2024 BIO CEO & Investor Conference

Retrieved on: 
Tuesday, February 20, 2024
Infection, Therapy, Fibromyalgia, TNX-102, Tonix Pharmaceuticals, Orphan drug, Smallpox, NIAID, Research, Annual report, NIH, CD40L, FDA, BIO, Prader–Willi syndrome, Sumatriptan, Government, Upsher-Smith Laboratories, Conference, Disease, Autoimmunity, University, COVID-19, PWS, Patient, Acute stress disorder, Security (finance), Long, Breakthrough therapy, Risk, IND, NDA, Failure, Long COVID, Cancer, Pharmaceutical industry

CHATHAM, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at the BIO CEO & Investor Conference on February 26, 2024 at 1:30 p.m.

Key Points: 
  • CHATHAM, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at the BIO CEO & Investor Conference on February 26, 2024 at 1:30 p.m.
  • Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering.
  • Tonix intends to meet with the FDA in the first half of 2024 and submit an NDA for the approval of Tonmya for the management of fibromyalgia in the second half of 2024.
  • A Phase 2 study of TNX-1300 is expected to be initiated in the first quarter of 2024.

UPSHER-SMITH AND THE NATIONAL ALLIANCE OF STATE PHARMACY ASSOCIATIONS (NASPA) ANNOUNCE EXCELLENCE IN INNOVATION AWARD RECIPIENTS

Retrieved on: 
Tuesday, February 6, 2024
Health, Pharmacy, Pharmacist, Upsher-Smith Laboratories, NASPA, National Alliance, Doctor of Pharmacy, JD

MAPLE GROVE, Minn., Feb. 6, 2024 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) and the National Alliance of State Pharmacy Associations (NASPA) proudly announce the recipients of the 2023 NASPA Excellence in Innovation Award.

Key Points: 
  • MAPLE GROVE, Minn., Feb. 6, 2024 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) and the National Alliance of State Pharmacy Associations (NASPA) proudly announce the recipients of the 2023 NASPA Excellence in Innovation Award.
  • The Excellence in Innovation Award recognizes qualified pharmacists who have demonstrated significant innovation in their practice, method, or service directly or indirectly resulting in improved patient care and/or advancement of the profession of pharmacy.
  • The award is presented by more than 40 participating state pharmacy associations throughout the year.
  • We are grateful to our longstanding partner, Upsher-Smith, and participating state pharmacy associations for their continued support of NASPA's Excellence in Innovation Award."

AmLactin® Announces Partnership with U.S. Figure Skating Champion Amber Glenn

Retrieved on: 
Tuesday, January 16, 2024
Olympic Games, Wollman Rink, Partnership, Lactic acid, Upsher-Smith Laboratories, Skin, Keratosis, Prize, United States national team, Ice, Cosmetics

BRIDGEWATER, N.J., Jan. 16, 2024 /PRNewswire/ -- AmLactin, the #1 dermatologist recommended moisturizer brand with lactic acid, is announcing today a one-year partnership with Team USA Figure Skater Amber Glenn for the #IAmLactinReady campaign where she will discuss her personal skincare journey with Keratosis Pilaris through a series of social posts that will run throughout 2024. Amber will also showcase how AmLactin keeps her skin soft and smooth, during the harsh winter months and throughout all the seasonal changes that can affect skin. 

Key Points: 
  • "I am thrilled to embark on this incredible mission with AmLactin for the #IAmLactinReady Uncover Your True Skin campaign," said Team USA Figure Skater Amber Glenn.
  • I hope my story can empower others on their road to uncovering their own true skin confidence," added Glenn.
  • To meet Amber Glenn in person and learn more about her skincare journey, play the #IAmLactinReady Instant Win Game at www.amlactin.com/pages/game for a chance to win.
  • "We are excited about this unique opportunity to partner with Amber Glenn for the #IAmLactinReady campaign.

Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in January: Focus is on TNX-102 SL for the Management of Fibromyalgia Following Positive Topline Results in Second Pivotal Phase 3 Trial

Retrieved on: 
Wednesday, January 3, 2024
Long COVID, Annual report, Hydrogen chloride, Upsher-Smith Laboratories, Long, Failure, Infection, Breakthrough therapy, NIAID, IND, Government, Research, FDA, Sumatriptan, Prader–Willi syndrome, NDA, Cancer, CD40L, Orphan drug, Risk, Disease, COVID-19, Fibromyalgia, Smallpox, Union, NIH, Patient, Therapy, Security (finance), Nature, PWS, Autoimmunity, Pharmaceutical industry

CHATHAM, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present and host investor meetings at the following January investor conferences:

Key Points: 
  • Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering.
  • Tonix’s priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia.
  • Tonix intends to meet with the FDA in the first half of 2024 and submit an NDA for the approval of TNX-102 SL for the management of fibromyalgia in the second half of 2024.
  • TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA.

Tonix Pharmaceuticals to Present at The National Academies Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures Public Meeting

Retrieved on: 
Monday, December 11, 2023
Long COVID, Hydrogen chloride, Long, Upsher-Smith Laboratories, Failure, National academy, Infection, Breakthrough therapy, NIAID, Binge eating disorder, Government, Research, Psychiatry, Sumatriptan, FDA, Pain, Prader–Willi syndrome, Cancer, CD40L, Orphan drug, Tonix Pharmaceuticals, Social anxiety disorder, Risk, COVID-19, Disease, Smallpox, CNS, Fibromyalgia, Obesity, Neurology, NIH, Central nervous system, Therapy, Security (finance), Annual report, Autoimmunity, Pharmaceutical industry

Dr. Lederman will participate in a panel discussion on Vaccine Research & Development taking place from 2:00 - 2:45 p.m.

Key Points: 
  • Dr. Lederman will participate in a panel discussion on Vaccine Research & Development taking place from 2:00 - 2:45 p.m.
  • A webcast of the meeting can be found here and will be available under the IR Events tab of the Tonix website at www.tonixpharma.com following the presentation.
  • Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering.
  • Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults.

Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in December

Retrieved on: 
Tuesday, November 28, 2023
Long COVID, Hydrogen chloride, Upsher-Smith Laboratories, Long, Failure, Infection, Breakthrough therapy, NIAID, Binge eating disorder, Government, Psychiatry, Research, Sumatriptan, FDA, Pain, Prader–Willi syndrome, Cancer, CD40L, Orphan drug, Social anxiety disorder, Risk, Disease, COVID-19, Fibromyalgia, Obesity, CNS, Smallpox, Virtual, Neurology, NIH, Central nervous system, Therapy, Security (finance), Annual report, Autoimmunity, Pharmaceutical industry

Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering.

Key Points: 
  • Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering.
  • Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults.
  • Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates.
  • Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions.

Ninth Annual Infantile Spasms Awareness Week Scheduled for December 1-7

Retrieved on: 
Monday, November 27, 2023
Brain, Research, Organization, Head, Movement, ISAN, Risk, Jerk, Patient, Colic, Epileptic spasms, Caregiver, Social media, Child, Mallinckrodt, Seizure, Spasm, Convulsion, Emergency, EEG, TSC, Front vowel, Upsher-Smith Laboratories, Brain damage, Pharmaceutical industry, ISAW

SILVER SPRING, Md., Nov. 27, 2023 /PRNewswire/ -- From December 1 to 7, 2023, a coalition of organizations will mark the Ninth Annual Infantile Spasms Awareness Week (ISAW).

Key Points: 
  • SILVER SPRING, Md., Nov. 27, 2023 /PRNewswire/ -- From December 1 to 7, 2023, a coalition of organizations will mark the Ninth Annual Infantile Spasms Awareness Week (ISAW).
  • The campaign is supported by the Infantile Spasms Awareness Network (ISAN), a coalition of 37 international organizations that have come together to inform families, healthcare providers and caregivers about the signs of infantile spasms.
  • "Because infantile spasms are a medical emergency, advocating for your baby is key and that's why Infantile Spasms Awareness Week is so important," said Kari Luther Rosbeck, President & CEO of the TSC Alliance®.
  • Infantile Spasms Awareness Week includes social media campaigns, national and local media interviews and physician awareness projects.

Tonix Pharmaceuticals Announces New Data Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) in Heart Xenotransplantation in Animal Models at the ACS Clinical Congress and IPITA-IXA-CTRMS Joint Congress

Retrieved on: 
Monday, October 30, 2023
Massachusetts General Hospital, Long, Faculty, Orphan drug, Research, American College, Prader–Willi syndrome, Gustav Neuring, Therapy, Obesity, Hydrogen chloride, Binge eating disorder, SL, COVID-19, Smallpox, Pain, Psychiatry, Sumatriptan, MDD, DSM-IV codes, Cell Transplantation, Social anxiety disorder, Upsher-Smith Laboratories, GE, Fibromyalgia, Transplant, MGH, Cancer, Central nervous system, Ischemia, Long COVID, Security (finance), Infection, CD40L, Congress, Survival, Disease, Breakthrough therapy, Animal, Planning, FDA, Autoimmunity, Government, CNS, Neurology, Risk, Science, ACS, PPAR, Annual report, Gujarat University of Transplantation Sciences, Failure, Pharmaceutical industry, Tonix Pharmaceuticals, CD154

CHATHAM, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced data from two oral presentations which were delivered recently at the American College of Surgeons (ACS) Clinical Congress 2023, and The International Pancreas and Islet Transplant Association (IPITA), the International Xenotransplantation Association (IXA), and the Cell Transplant and Regenerative Medicine Society (CTRMS) Joint Congress by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital (MGH) in October 2023. The data involve Tonix’s TNX-1500 (Fc-modified dimeric anti-CD40L monoclonal antibody [mAb]) which is currently in Phase 1 development for the prevention of organ transplant rejection. Copies of the presentations are available under the Scientific Presentations tab of the Tonix Pharmaceuticals website at www.tonixpharma.com.

Key Points: 
  • The data involve Tonix’s TNX-1500 (Fc-modified dimeric anti-CD40L monoclonal antibody [mAb]) which is currently in Phase 1 development for the prevention of organ transplant rejection.
  • Copies of the presentations are available under the Scientific Presentations tab of the Tonix Pharmaceuticals website at www.tonixpharma.com .
  • include data demonstrating the use of TNX-1500 as maintenance therapy after xeno heart transplant in non-human primates.
  • In both studies, genetically engineered (GE) pigs in baboon transplants were treated with cold-perfused ischemia minimization and a novel costimulation-based immunosuppressive regimen including TNX-1500.

THERESA TOLLE NAMED 2023 NCPA WILLARD B. SIMMONS INDEPENDENT PHARMACIST OF THE YEAR

Retrieved on: 
Tuesday, October 17, 2023
Pharmacist, American Pharmacists Association, Medication therapy management, Upsher-Smith Laboratories, Automotive Executive of the Year Award, Health, NCPA, National Association, Trustee, University of Florida College of Pharmacy, University, MTM, Florida College, Lead, SAFIR, Patient, Pharmaceutical industry, Health care, Nursing, Pharmacy

MAPLE GROVE, Minn., Oct. 17, 2023 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) is pleased to announce that Theresa Tolle, BSPharm, FAPhA, owner of Bay Street Pharmacy in Sebastian, Florida, is the winner of the 2023 National Community Pharmacists Association (NCPA) Willard B. Simmons Independent Pharmacist of the Year award. Tolle was honored with the award on Monday, October 16 at NCPA's Annual Convention and Expo in Orlando, FL.

Key Points: 
  • MAPLE GROVE, Minn., Oct. 17, 2023 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) is pleased to announce that Theresa Tolle, BSPharm, FAPhA, owner of Bay Street Pharmacy in Sebastian, Florida, is the winner of the 2023 National Community Pharmacists Association (NCPA) Willard B. Simmons Independent Pharmacist of the Year award.
  • Tolle was honored with the award on Monday, October 16 at NCPA's Annual Convention and Expo in Orlando, FL.
  • The annual award is given to a pharmacist who exhibits exemplary professional leadership, service to community, and commitment to independent pharmacy.
  • The award is named in honor of Willard B. Simmons, a former executive secretary of NCPA (then known as the National Association of Retail Druggists) and a longtime trustee of the NCPA Foundation.